SciSparc (SPRC) Consolidated Net Income (2016 - 2022)
SciSparc (SPRC) posted Consolidated Net Income of -$359000.0 for Q4 2022, down 113.14% sequentially from $2.7 million in Q3 2022.
SciSparc (SPRC) Consolidated Net Income (2016 - 2022) Analysis & Trends
SciSparc has reported Consolidated Net Income for 5 years, with the latest figure at -$359000.0 in Q4 2022.
- Quarterly Consolidated Net Income changed N/A year-over-year to -$359000.0 in Q4 2022, while the trailing twelve-month figure through Jun 2024 was -$359000.0 (down 115.13% YoY) and the FY2025 annual result came in at -$12.6 million, down 68.15% from the prior year.
- Consolidated Net Income slipped to -$359000.0 in Q4 2022 per SPRC's latest filing, from $2.7 million in the prior quarter.
- Over five years, Consolidated Net Income peaked at $2.7 million in Q3 2022 and troughed at -$12.3 million in Q4 2018.
- A 3-year average of -$1.0 million and a median of $140500.0 in 2018 frame the typical range for Consolidated Net Income.
- The sharpest annual moves came in 2018 and 2019: Consolidated Net Income slumped 79.48% in 2018, then jumped 2104.76% in 2019.
- Over 3 years, Consolidated Net Income stood at -$12.3 million in 2018, then surged by 101.6% to $197000.0 in 2019, then plunged by 282.23% to -$359000.0 in 2022.
- According to Business Quant data, Consolidated Net Income over the past three periods registered -$359000.0, $2.7 million, and $197000.0 for Q4 2022, Q3 2022, and Q2 2019 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -174.37 Mn |
| 10 | SciSparc | 836,385.99 | 836,385.99 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -359,000.00 |
| Sep 30, 2022 | 2.73 Mn |
| Jun 30, 2019 | 197,000.00 |
| Mar 31, 2019 | 1.85 Mn |
| Dec 31, 2018 | -12.33 Mn |
| Sep 30, 2018 | 1.14 Mn |
| Jun 30, 2018 | -1.48 Mn |
| Mar 31, 2018 | 84,000.00 |
| Dec 31, 2017 | -6.87 Mn |
| Sep 30, 2017 | -116,000.00 |
| Jun 30, 2017 | -1.74 Mn |
| Mar 31, 2017 | -315,000.00 |
| Dec 31, 2016 | -1.97 Mn |
| Sep 30, 2016 | -17,000.00 |
| Jun 30, 2016 | -18,000.00 |